non-steroidal aromatase inhibitor
1 abstract
Abstract
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.Org: UCLA Santa Monica Hematology/Oncology Regulatory-2, Novartis Healthcare Private Limited, Novartis Ireland,